Advancing Treg Cell Therapy with 3 Engineered Genes for Improved Specificity, Stability & Safety

Time: 2:00 pm
day: Day One | Track A | Morning


  • Explaining the science behind Quell’s approach to building a Treg cell therapy in autoimmunity, inflammation and transplant rejection
  • Reflecting on preclinical data to explain improved antigen specificity and stability model for generating efficacious and safe products
  • Glimpsing at clinical development of Quell’s Treg therapy, from Treg population isolation to expansion, clinical design and clinical outcomes to further understand the technology